Saturday 17 October 2026
Export CYTOF’s income statement to Excel — free account
Altamira Therapeutics Ltd.
CYTOF Healthcare Biotechnology
Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
0.09
0.00
0.00%
Follow CYTOF
Altamira Therapeutics Ltd. (CYTOF) P/E ratio
Altamira Therapeutics Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| BBLG Bone Biologics Corp. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| MNTRQ 9 Meters Biopharma, Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)